Clinical trials
Recurrent or Metastatic Cervical Cancer clinical trials
Below are recruiting recurrent or metastatic cervical cancer clinical trials, each written for real people, not researchers. We’re tracking 3,847 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07412314Recruiting
Proton Therapy for Recurrent Nasopharyngeal Cancer
This trial uses proton therapy (a precise type of radiation) to treat people whose nasopharyngeal cancer has come back. It aims to see if this treatment can help control the cancer while limiting side effects.
Guangzhou, GuangdongAges 18 years+ - NCT07398326RecruitingPhase 2
Drug combo for advanced colorectal cancer that hasn't spread to the liver
This trial tests a combination of two drugs (anlotinib and sintilimab) as a first treatment for people with advanced colorectal cancer that has spread to places other than the liver, who do not want chemotherapy. The goal is to see if this targeted therapy can help control the cancer.
ShanghaiAges 18 years+ - NCT07400354Recruiting
PD-1 drug plus chemo for advanced stomach cancer based on gut bacteria
This trial tests if adding a PD-1 immunotherapy drug to standard chemotherapy works better for advanced stomach cancer, and looks at how your gut bacteria may affect treatment. It is for people who have not had chemotherapy before and are starting their first treatment.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07395505Enrolling by invitation
Surgery for advanced rectal or anal cancer
This trial studies the results of a major surgery called pelvic exenteration for patients with advanced rectal or anal cancer that has spread to nearby tissues or bones but not to distant organs. The goal is to see how well the surgery works and how patients recover afterward.
TaoyuanAges 20 years+ - NCT07392346RecruitingPhase 2
Fruquintinib combo for advanced gastric cancer after immunotherapy
This trial tests a combination of targeted therapy (fruquintinib), chemotherapy (nab-paclitaxel), and two immunotherapies (iparomlimab and tuvonralimab) for people with advanced stomach or gastroesophageal junction cancer whose first treatment with a PD-1/PD-L1 inhibitor stopped working. The goal is to see if this new combination can shrink tumors and improve outcomes.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06225843RecruitingPhase 2
Testing a new drug combo before liver surgery for colorectal cancer
This trial is for people with colorectal cancer that has spread to the liver. It tests whether adding a new drug (sotevtamab) to standard chemotherapy (FOLFOX) before surgery can help shrink tumors and improve outcomes.
Montreal, QuebecAges 18 years+ - NCT06840418Recruiting
New imaging to find cancer spread in cervical cancer surgery
This study tests a new imaging technique (NIRFI with ICG dye) to help surgeons see if cervical cancer has spread to lymph nodes during your hysterectomy surgery. It may help guide more precise removal of affected nodes.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05464875Recruiting
Testing avapritinib for advanced GI stromal tumors
This study looks at how well avapritinib works and how safe it is for people with metastatic or unresectable gastrointestinal stromal tumors (GIST). It focuses on whether the tumor has certain marker and gene features and whether you can tolerate related medications.
GuangzhouAges 18 years+ - NCT06763029RecruitingPhase 2
Study of three drugs for advanced colorectal cancer after first treatment
This trial tests a combination of three drugs (irinotecan liposomes, cetuximab, and vemurafenib) for people with advanced colorectal cancer that has a specific genetic change (BRAF V600E mutation) and did not respond to first treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07340424RecruitingEarly Phase 1
Study of 225Ac-TR2205 for triple-negative breast cancer
This trial tests a new radioactive drug called 225Ac-TR2205 for people with triple-negative breast cancer that has spread. The goal is to see if it is safe and tolerable. It may be an option if you have tried at least two other treatments, including one for metastatic disease.
Jinan, ShandongAges 18 years+ - NCT04196257RecruitingPhase 1
Early-dose trial of BP1001-A for advanced or recurrent solid tumors
This Phase 1 trial studies BP1001-A in people with advanced or recurring solid cancers to find a safe dose and learn how the treatment works. You may be asked for tumor biopsies before and possibly after treatment to see how the cancer responds.
Silver Spring, MarylandAges 18 years+ - NCT07332507RecruitingPhase 1
Testing teclistamab for recurrent plasmablastic lymphoma
This trial tests a new drug called teclistamab for people with plasmablastic lymphoma that has come back or not responded to standard treatments. The goal is to see if teclistamab can shrink tumors and control the disease.
Duarte, CaliforniaAges 18 years+ - NCT07332247RecruitingPhase 2
Immunotherapy plus chemo then immediate vs selective re-radiation for advanced recurrent NPC
This trial is for people with nasopharyngeal cancer that has come back in the same area. It tests whether giving additional radiation right after chemo plus immunotherapy works better than waiting to see if more radiation is needed later.
Guangzhou, GuangdongAges 18–70 - NCT07326800Recruiting
Meditation and values program for breast cancer patients
This trial tests a program called MAEva that combines meditation and acceptance techniques to help patients with non-metastatic breast cancer. It aims to improve well-being by focusing on personal values and coping skills.
Vandœuvre-lès-NancyAges 18 years+ - NCT06201078RecruitingPhase 2
Second radiation for prostate cancer that returns locally
This trial tests a second round of precise, high-dose radiation (stereotactic body radiotherapy) for men whose prostate cancer has come back only in the prostate after their first radiation treatment. It aims to control the recurrence with fewer side effects.
GliwiceAges 18–80 - NCT06791460RecruitingPhase 2/Phase 3
A study of two drug combinations for ovarian cancer that came back
This trial tests a common chemotherapy (Pegylated Liposomal Doxorubicin) plus an immunotherapy (Adebrelimab), with or without a bladder medication (Mirabegron), in people whose ovarian cancer has returned after initial treatment. The goal is to see if adding Mirabegron helps the other drugs work better.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07284849RecruitingPhase 3
Testing a new drug combo for advanced colorectal cancer
This trial tests whether adding an experimental drug (INCA33890) to standard chemotherapy and bevacizumab helps people with a certain type of advanced colorectal cancer. It is for those whose cancer has spread and has not been treated yet with systemic therapy.
Mobile, AlabamaAges 18 years+ - NCT07283679RecruitingPhase 1/Phase 2
NK cell therapy with two immune agents for returning lymphoma
This trial tests a new combination of specially grown immune cells (NK cells) plus two drugs that help them attack cancer. It's for people with a type of B-cell lymphoma that came back after at least two prior treatments or a stem cell transplant, and who have either failed or are not eligible for CAR-T cell therapy.
Houston, TexasAges 18 years+ - NCT07282808Recruiting
Focal vs. full prostate treatment study
This trial tests whether targeting only the visible cancer spots on MRI (focal therapy) works as well as treating the whole prostate, for men with small, moderate-risk prostate cancer that hasn't spread.
SingaporeAges 21 years+ - NCT05169112RecruitingPhase 3
Hormone therapy to prevent prostate cancer coming back
This trial studies whether hormone therapy (also called ADT) after prostate surgery lowers the chance that prostate cancer will return. It targets people with very low PSA after surgery but with a higher predicted risk of recurrence.
Halifax, Nova ScotiaAges 18 years+ - NCT07277764RecruitingPhase 2
Radiation and immunotherapy for returning nasopharyngeal cancer
This trial tests a combination of high and low dose radiation plus an immunotherapy drug (PD-1 inhibitor) for people whose nasopharyngeal cancer has come back after previous treatment. The goal is to see if this approach can be more effective while reducing side effects.
Nanchang, JiangxiAges 18–75 - NCT06894576Recruiting
Creating a risk score for blood clot recurrence and bleeding in cancer patients
This study is for people with cancer who have had a serious blood clot. Researchers want to create a risk score that predicts who might have another clot or a bleeding problem from treatment, so they can better tailor care.
Ottawa, OntarioAges 18 years+ - NCT07261683RecruitingPhase 2
Combination therapy for recurrent ovarian cancer
This trial tests a new combination of chemotherapy, immunotherapy, and a bladder relaxant for ovarian cancer that has come back after initial treatment. It aims to see if adding these drugs together can help control the cancer longer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07258108RecruitingPhase 2
Sac-TMT and KL-A167 for HR+/HER2- Breast Cancer
This trial is testing a combination of two drugs, Sac-TMT and KL-A167, in people with a certain type of advanced breast cancer (HR+/HER2-) that is PD-L1 positive. It's for those whose cancer has gotten worse after treatment with a CDK4/6 inhibitor and hormone therapy.
Guangzhou, GuangdongAges 18–75
Hear when a new Recurrent or Metastatic Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic cervical cancer?
- Yes. Clin2 currently lists 3,847 recruiting recurrent or metastatic cervical cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic cervical cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic cervical cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.